NCT03683277: Phase 2: Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

IFM2014-01

NCT03683277: Phase 2: Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.

Sponsor:

Intergroupe Francophone du Myelome

Collaborators:

AXONAL

Nantes University Hospital

University Hospital, Grenoble

Euraxi Pharma

Location

France

---

ClinicalTrials.gov Identifier: NCT03683277

Official Title: Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

First Posted : September 25, 2018

Click here to see details on ClinicalTrials.gov

https://www.myelome.fr/

---

Drug: Ixazomib/Pomalidomide/Dexamethasone

---